Department of Pediatrics, College of Medicine, Jeju National University, Jeju, Republic of Korea.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2059308. doi: 10.1080/21645515.2022.2059308. Epub 2022 Apr 6.
The Food and Drug Administration (FDA) expanded the emergency use authorization for the BNT162b2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech) for children aged 12-15 years on 10 May 2021. To date, less than a year has passed since vaccination against COVID-19 has been used in children and adolescents, and the overall effects and safety of these vaccines are still being assessed. The BNT162b2 vaccine originally had a favorable profile in 12-17-year-old recipients compared with older ages, and no serious adverse events had previously been reported. Despite various adverse events, the benefit of reducing the infection rate or the frequency of severe COVID-19 has been evaluated to outweigh the harm caused by COVID-19 vaccination. Additionally, several cases of sudden development of new-onset or relapsing glomerular diseases, including acute kidney injury (AKI), have been reported in adults following the BNT162b2 SARS-CoV-2 mRNA vaccine. Herein, we present two cases of adolescents who developed AKI following the second administration of the BNT162b2. These are the first pediatric cases of acute tubulointerstitial nephritis temporarily linked to SARS-CoV-2 vaccination.
美国食品和药物管理局（FDA）于 2021 年 5 月 10 日扩大了 BNT162b2 信使 RNA（mRNA）疫苗（辉瑞-生物技术）在 12-15 岁儿童中的紧急使用授权。迄今为止，儿童和青少年接种 COVID-19 疫苗还不到一年，这些疫苗的总体效果和安全性仍在评估中。与年龄较大的人群相比，BNT162b2 疫苗最初在 12-17 岁的受种者中具有良好的特征，此前没有报告过严重的不良事件。尽管存在各种不良反应，但评估认为，降低感染率或 COVID-19 重症的发生频率带来的益处大于 COVID-19 疫苗接种造成的危害。此外，在 BNT162b2 针对 SARS-CoV-2 的 mRNA 疫苗接种后，成年人中报告了几例新发病例或复发性肾小球疾病（包括急性肾损伤（AKI））的突然发作病例。在此，我们报告了两例青少年在接种 BNT162b2 第二剂后发生 AKI 的病例。这些是与 SARS-CoV-2 疫苗接种暂时相关的儿童首例急性肾小管间质性肾炎的病例。
